Technology | January 12, 2012

Hyperthermia System Increases Cervical Cancer Response to Radiation Therapy

 

January 12, 2012 -- The U.S. Food and Drug Administration (FDA) recently cleared a hyperthermia system designed to warm cervical cancer tumors so they respond better to radiation therapy treatments.

The BSD Medical BSD-2000 Hyperthermia System delivers focused therapeutic heating (hyperthermia) with temperatures greater than 104 degrees Fahrenheit, to cancerous tumors by applying radiofrequency (RF) energy. The energy is delivered in the frequency range of 75 to 120 MHz. The BSD-2000 delivers RF energy to a patient using a power source and an array of antennae that surround the patient’s body. The energy can be electronically focused to produce a localized electromagnetic power field. This can be adjusted to target the three-dimensional shape, size and location of the tumor, providing dynamic control of the heat delivered to the tumor region. This method of therapeutic heating utilizes the adjustment of frequency, phase, and amplitude from multiple power sources, along with an applicator selection and patient positioning, to optimize heating of the targeted body tissues.

The system is indicated for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The FDA said it increases the response of tumor cells to radiation therapy.

The FDA said the system should not be used in patients who have:

  • medical devices that are implanted, carried or worn on their bodies
  • severe dysfunction of the heart or lungs
  • electrically conductive, metal, or foreign objects in, on or attached to their body
  • severe high or low blood pressure
  • severe cerebrovascular disease, or
  • when the treating physician cannot place either a temperature sensor into the tumor or into a body cavity.

For a summary of safety and probable benefit (SSPB) and product labeling, visit www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=h090002

 

 

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init